Editorial: KRAS in stage IV non-small cell lung cancer

Editorial: KRAS in stage IV non-small cell lung cancer

Saved in:

Bibliographic Details
Main Authors:	Anneloes L. Noordhof, Torsten Gerriet Blum, Georgia Hardavella, Lizza E. L. Hendriks, Wouter H. van Geffen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-03-01
Series:	Frontiers in Oncology
Subjects:	non-small cell lung cancer lung adenocarcinoma Kirsten Rat Sarcoma (KRAS) KRAS G12C KRAS inhibitors
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1517049/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy
by: İsa Taş, et al.
Published: (2025-04-01)

Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer
by: Eszter Molnár, et al.
Published: (2024-12-01)

Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways
by: Hnin Ei Ei Khine, et al.
Published: (2025-04-01)

Sotorasib Is Not Effective in a KRAS‐Mutated Patient With Brain Metastases From Lung Adenocarcinoma due to Multiple Gene Co‐Mutations
by: Takayuki Suetsugu, et al.
Published: (2025-05-01)

KRAS-mutated non-small cell lung cancer: new therapy strategies
by: K. K. Laktionov, et al.
Published: (2024-05-01)

Dual inhibition of GTP-bound KRAS and mTOR in lung adenocarcinoma and squamous cell carcinoma harboring KRAS G12C
by: Masaoki Ito, et al.
Published: (2025-05-01)

Targeting KRAS: from metabolic regulation to cancer treatment
by: Yanyan Shi, et al.
Published: (2025-01-01)

Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer
by: Nawaz Khan, et al.
Published: (2025-07-01)

Elevated KRAS protein level is associated with better survival in pancreatic cancer
by: S. M. Stålberg, et al.
Published: (2025-07-01)

Advances in Immunotherapy of KRAS-mutated Non-small Cell Lung Cancer
by: Xinyue YANG, et al.
Published: (2025-05-01)

KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential
by: Metin Eser, et al.
Published: (2024-11-01)

Mapping the Interactome of KRAS and Its G12C/D/V Mutants by Integrating TurboID Proximity Labeling with Quantitative Proteomics
by: Jiangwei Song, et al.
Published: (2025-04-01)

The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis
by: Rui Zhao, et al.
Published: (2024-11-01)

Analysis and characterization of chondroitin/dermatan sulfate composition of lung adenocarcinoma tissues with different types of genetic alterations in ALK, EGFR and KRAS oncogenes
by: Domonkos Pál, et al.
Published: (2025-06-01)

KRAS4B is required for placental development
by: Marie-Albane Minati, et al.
Published: (2025-08-01)

Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer
by: Soo-Yeon Hwang, et al.
Published: (2025-05-01)

An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti‐Angiogenic Agents for Therapy: A Case Report
by: Li Wang, et al.
Published: (2025-06-01)

A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations
by: Jonathan W. Riess, MD, MS, et al.
Published: (2025-06-01)

ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer
by: Mohamed I Saad, et al.
Published: (2019-03-01)

Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity
by: Jungeun Lee, et al.
Published: (2022-12-01)

Tumor-specific delivery of KRAS siRNA with iRGD-exosomes efficiently inhibits tumor growth
by: Yu Zhou, et al.
Published: (2019-12-01)

Comparative effects of combustible cigarette versus electronic cigarette exposures on KRAS mutant lung cancer promotion
by: Walter V. Velasco, et al.
Published: (2025-09-01)

Design, Synthesis, Anticancer Evaluation and Molecular Docking of Pyrimidine, Pyrido[4,3-d]pyrimidine and 5,6,7,8-Tetrahydropyrido[3,4-d]pyrimidine Derivatives as Novel KRAS-G12D Inhibitors and PROTACs
by: Hailong Yang, et al.
Published: (2025-05-01)

KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors
by: Linyan Tian, et al.
Published: (2025-01-01)

Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening
by: Yajing Liu, et al.
Published: (2025-06-01)

Histiocytic sarcoma involving multiple abdominal sites: A rare case with KRAS mutation and response to ICE chemotherapy
by: Shahad Khalid Hussein Hussein, MD, et al.
Published: (2025-07-01)

Correlation of PD-L1 and HIF-1 Alpha Expression with KRAS Mutation and Clinicopathological Parameters in Non-Small Cell Lung Cancer
by: Seda Er Özilhan, et al.
Published: (2025-02-01)

Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report
by: Andrea De Giglio, et al.
Published: (2024-12-01)

The impact of KRAS mutations on the tumour microenvironment and treatment response in non-small cell lung cancer
by: Guomin Gu, et al.
Published: (2024-12-01)

Case report of metastatic colorectal cancer associated with <i>KRAS</i> A146V and A59G mutations
by: O. I. Kit, et al.
Published: (2023-07-01)

Acetylation-induced degradation of ECHS1 enhances BCAA accumulation and proliferation in KRAS-mutant colorectal cancer
by: Zhenkang Li, et al.
Published: (2025-05-01)

SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells
by: Lei Jiang, et al.
Published: (2019-12-01)

Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
by: Shenao Fu, et al.
Published: (2025-07-01)

A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR
by: Song Han, et al.
Published: (2025-01-01)

Distinct association of HRAS and KRAS with Mn2+ ion illustrated by paramagnetic NMR
by: Jia-Liang Chen, et al.
Published: (2025-02-01)

The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer
by: A. N. Toropovskiy, et al.
Published: (2022-11-01)

Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review
by: Fan Zhang, et al.
Published: (2025-04-01)

An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy
by: Keke Ma, et al.
Published: (2025-08-01)

Motif-guided identification of KRAS-interacting proteins
by: Sanan Wu, et al.
Published: (2024-11-01)

Mechanistic Foundations of KRAS‐Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment
by: Jiayao Ma, et al.
Published: (2025-08-01)